To contentTo navigationTo search

Implantica announces it will merge with Implantica MediSwiss AG

 | Regulatory

Implantica AG (publ) today announces that it will perform a downstream merger with its holding company, Implantica MediSwiss AG. This merger will not affect the shareholding of the existing shareholders in Implantica AG but will increase the free float for the benefit of all shareholders.

This downstream merger implies no change and no share dilution for the existing shareholders in Implantica AG, yet it will enable the shareholders in Implantica MediSwiss AG to exchange their indirect shareholding into a direct shareholding in Implantica AG, the publicly listed entity. The one year lock-up period commencing September 21, 2020, signed by all Implantica MediSwiss AG shareholders, remains in effect.

“Merging the parent company, Implantica MediSwiss, with the publicly listed Implantica AG is advantageous for our shareholders. Not only will it simplify the group structure, it will also increase the free float with the additional MediSwiss shareholders, and provide more liquidity for the Implantica AG shares,” said Peter Forsell, CEO.

For further information, please contact:

Nicole Pehrsson, Investor Relations
Telephone (CH): +41 (0)79 335 09 49

Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.

The company's Certified Adviser is FNCA Sweden AB, +46 (0)8 528 00 399,

The information was sent for publication, through the agency of the contact person set out above, on August 17, 2021 at 17:20 CET.

About Implantica

Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit for further information.